John R. Lydeard

The paper develops a proteogenomic framework to identify dispensable genes for safer gene editing in hematopoietic therapies, identifying 237 candidates including LY75.

The paper identifies sequencing artifacts in gRNA purity assessment and introduces FUSS-seq to reduce them, improving accuracy for CRISPR-based therapeutics.

This study evaluates ADGRE2 as an AML target, showing efficient gene editing in HSPCs to protect against myelotoxicity and developing ADGRE2-specific CAR T cells for therapy.

The paper constructs a single-cell DNA sequencing atlas and introduces GUMM, a computational workflow, to accurately infer gene editing allelism despite technical artifacts.